These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38992418)

  • 1. Reliable business case for repurposing of existing medicines requires key changes in government policies.
    de Visser SJ; van den Berg S; Mosterd A; Lo DC
    Drug Discov Today; 2024 Sep; 29(9):104096. PubMed ID: 38992418
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing Drugs in Oncology: Next Steps.
    Verbaanderd C; Meheus L; Huys I; Pantziarka P
    Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments.
    Juárez-López D; Schcolnik-Cabrera A
    Arch Med Res; 2021 Apr; 52(3):243-251. PubMed ID: 33190955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and opportunities of drug repositioning.
    Novac N
    Trends Pharmacol Sci; 2013 May; 34(5):267-72. PubMed ID: 23582281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs.
    Kesselheim AS; Tan YT; Avorn J
    Health Aff (Millwood); 2015 Feb; 34(2):286-93. PubMed ID: 25646109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug repurposing from the perspective of pharmaceutical companies.
    Cha Y; Erez T; Reynolds IJ; Kumar D; Ross J; Koytiger G; Kusko R; Zeskind B; Risso S; Kagan E; Papapetropoulos S; Grossman I; Laifenfeld D
    Br J Pharmacol; 2018 Jan; 175(2):168-180. PubMed ID: 28369768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advocating for mutually beneficial access to shelved compounds.
    Pulley JM; Jerome RN; Shirey-Rice JK; Zaleski NM; Naylor HM; Pruijssers AJ; Jackson JC; Bernard GR; Holroyd KJ
    Future Med Chem; 2018 Jun; 10(12):1395-1398. PubMed ID: 29788759
    [No Abstract]   [Full Text] [Related]  

  • 9. New Antimicrobial Approaches: Reuse of Old Drugs.
    Savoia D
    Curr Drug Targets; 2016; 17(6):731-8. PubMed ID: 26245476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research.
    Vanhaelen Q
    Curr Med Chem; 2021; 28(1):181-195. PubMed ID: 32003659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity.
    Power A; Berger AC; Ginsburg GS
    JAMA; 2014 May; 311(20):2063-4. PubMed ID: 24867009
    [No Abstract]   [Full Text] [Related]  

  • 12. Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance.
    Bloom BE
    Assay Drug Dev Technol; 2015 Dec; 13(10):606-11. PubMed ID: 26284286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing drugs in oncology: From candidate selection to clinical adoption.
    Pantziarka P; Verbaanderd C; Huys I; Bouche G; Meheus L
    Semin Cancer Biol; 2021 Jan; 68():186-191. PubMed ID: 31982510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Envisioning an actionable research agenda to facilitate repurposing of off-patent drugs.
    Austin CP; Mount BA; Colvis CM
    Nat Rev Drug Discov; 2021 Oct; 20(10):723-724. PubMed ID: 34045734
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug repurposing in the era of COVID-19: a call for leadership and government investment.
    Martin JH; Bowden NA
    Med J Aust; 2020 Jun; 212(10):450-452.e1. PubMed ID: 32372435
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioneering government-sponsored drug repositioning collaborations: progress and learning.
    Frail DE; Brady M; Escott KJ; Holt A; Sanganee HJ; Pangalos MN; Watkins C; Wegner CD
    Nat Rev Drug Discov; 2015 Dec; 14(12):833-41. PubMed ID: 26585533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework.
    Abu-Zahra T; Grimm SE; Scholte M; Raymakers AJN; Kesselheim AS; Joore M
    Drug Discov Today; 2024 Jun; 29(6):104008. PubMed ID: 38692506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Analytical Review of Computational Drug Repurposing.
    Sadeghi SS; Keyvanpour MR
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(2):472-488. PubMed ID: 31403439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Medicines Repurposing Program - a critical perspective.
    Ghinea N
    Aust Health Rev; 2024 Jun; 48(3):259-261. PubMed ID: 38710479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on Drug Repurposing.
    Schcolnik-Cabrera A; Juárez-López D; Duenas-Gonzalez A
    Curr Med Chem; 2021; 28(11):2085-2099. PubMed ID: 32867630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.